newsfilter
← Latest News
PR Newswire·

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

  • Karyopharm Therapeutics Inc. will hold a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 8:10 a.m. ET in New York, NY.
  • The event will feature the company's senior management team \& a live webcast will be available via the Investors \& Media section of the company website with a replay option.
  • Karyopharm is a commercial-stage pharmaceutical company pioneering nuclear export inhibition therapies for cancer patients.
  • The company's lead therapy, XPOVIO® (selinexor), is a first-in-class exportin 1 (XPO1) inhibitor marketed in the U.S. for relapsed or refractory multiple myeloma.
  • XPOVIO or NEXPOVIO® is approved in more than 50 ex-U.S. countries \& territories.
  • The company is advancing selinexor in hematologic \& solid tumor cancers, including myelofibrosis \& TP53 wild-type endometrial cancer.
  • Karyopharm is evaluating XPO1 inhibition across myeloproliferative neoplasms \& TP53 wild-type solid tumors using next-generation compounds like eltanexor.
  • The company is headquartered in Newton, Massachusetts, \& maintains a commercial infrastructure to deliver novel cancer therapeutic options.